Clinical trial
Single Dose Study to Assess the Safety, Tolerability, Concentration in Body and…
NCT00422175 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00422175 |
|---|---|
| Title | Single Dose Study to Assess the Safety, Tolerability, Concentration in Body and Effect of BAF312 |
| Official title | A First-in-Human Study for BAF312: A Two Parts, Single Center, Randomized, Double-Blind, Placebo-Controlled Ascending Single Dose Study to Explore the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral BAF312 in Healthy Volunteers |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Healthy |
| Intervention type | Drug |
| Interventions | BAF 312 |
| Enrollment | 63 |
| Start date | Oct 1, 2006 |
| Completion | Nov 1, 2007 |
| First posted | Jan 15, 2007 |
| Last update posted | Nov 29, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: